Hunting an early FDA OK, Ignyta surges on promising snapshot of lung cancer data
Shares of Ignyta $RXDX erupted this morning after the biotech reported that its carefully calibrated approach to non-small cell lung cancer had paid off with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
